Spyre Therapeutics (SYRE) earnings

Healthcare · Biotechnology · Market cap $7.2B

In the quarter ended June 2026, Spyre Therapeutics had revenue of —.

On August 4, 2026 it reported EPS of -0.36 against an estimate of -0.71 (beat).

The next report is expected on Tuesday, November 3, 2026, with EPS expected around -0.79.

Report dates

ReportDateTimeEPS estimateEPS reported
NextTue Nov 3, 2026 — -0.79 —
LastTue Aug 4, 2026 — -0.71 -0.36

Dates from company announcements and exchange calendars; estimates are the consensus where available. See the full earnings calendar.

Quarterly results

The last 12 quarters from Spyre Therapeutics's 10-Q and 10-K filings with the SEC. Growth is against the same quarter a year earlier. EPS here is GAAP diluted EPS as filed; the reported EPS compared with estimates above can be on the company's adjusted basis, so the two can differ.

Quarter endedRevenueGrowthEPS (diluted)GrowthOp. marginFiled
Jun 30, 2026— — — — — 2026-08-04
Mar 31, 2026— — -0.74 — — 2026-05-05
Dec 31, 2025— — — — — 2026-02-19
Sep 30, 2025— — — — — 2025-11-04
Jun 30, 2025— — — — — 2025-08-05
Mar 31, 2025— — — — — 2025-05-08
Dec 31, 2024$0 — — — — 2025-02-27
Sep 30, 2024$0 — 1.06 +23.3% — 2024-11-07
Jun 30, 2024$0 — 0.59 -98.5% — 2024-08-07
Mar 31, 2024$0 — 0.72 — — 2024-05-09
Dec 31, 2023$0 — — — — 2024-02-29
Sep 30, 2023$0 — 0.86 — — 2023-11-09
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for SYRE.
Open SYRE in Investingly

Questions

When does Spyre Therapeutics report earnings?

Spyre Therapeutics's next earnings report is expected on November 3, 2026.

How did Spyre Therapeutics do last quarter?

In the quarter ended June 2026, Spyre Therapeutics had revenue of —.

From Spyre Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.